title: Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma.
abstract: OBJECTIVE
  In this study, we tried to evaluate the efficacy of locoregional treatment (LRT) in patients with metastatic breast carcinoma (MBC).
  
  
  METHODS
  The medical records of 227 patients with MBC at initial presentation between April 1999 and January 2013 were retrospectively evaluated. The median age at diagnosis was 50 years (range, 27-83 years). Thirty-nine patients (17%) had no LRT. Among patients who had LRT, 2 (1%) had locoregional radiotherapy (RT) alone, 54 (29%) had surgery alone [mastectomy, n = 50; breast conserving surgery (BCS), n = 4] and 132 (70%) had surgery (mastectomy, n = 119; BCS, n = 13) followed by locoregional RT.
  
  
  RESULTS
  The median follow-up time was 35 months (range, 4-149 months). Five-year OS and PFS rates were 44% and 20%, respectively. In both univariate and multivariate analysis LRT per se did not affect OS and PFS rates. However, the 5-year OS and PFS rates were significantly higher in patients treated with locoregional RT than the ones who were not. The corresponding rates were 56% vs. 24% for OS and 27% vs. 7% for PFS (p < 0.001). Median survival was 67 months and 37 months, respectively.
  
  
  CONCLUSIONS
  Our study showed that patients with MBC who received postoperative locoregional RT may have a survival advantage compared with patients who were only treated by surgery. A phase III trial testing the role of adjuvant locoregional RT may help to distinguish patients who will benefit from adjuvant RT.
authors.affiliation: Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey.
authors.forename: Melis
authors.initials: M
authors.lastname: Gultekin
authors.affiliation: Medical Oncology Clinic, Education and Research Hospital, Ankara Numune Hospital, Ankara, Turkey.
authors.forename: Ozan
authors.initials: O
authors.lastname: Yazici
authors.affiliation: Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey.
authors.forename: Gulnihan
authors.initials: G
authors.lastname: Eren
authors.affiliation: Department of Preventive Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Yuce
authors.affiliation: Department of Medical Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.affiliation: Department of Medical Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Ozisik
authors.affiliation: Department of Medical Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.
authors.forename: Nilufer
authors.initials: N
authors.lastname: Guler
authors.affiliation: Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey.
authors.forename: Gozde
authors.initials: G
authors.lastname: Yazici
authors.affiliation: Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey.
authors.forename: Pervin
authors.initials: P
authors.lastname: Hurmuz
authors.affiliation: Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey. Electronic address: fyildiz@hacettepe.edu.tr.
authors.forename: Ferah
authors.initials: F
authors.lastname: Yildiz
authors.affiliation: Department of Medical Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.affiliation: Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Gurkaynak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology / Q000628:therapy*; D018275:Carcinoma, Lobular / Q000473:pathology / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008408:Mastectomy; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011878:Radiotherapy; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016896:Treatment Outcome
keywords: Chemotherapy; Locoregional treatment; Metastatic breast carcinoma; Radiotherapy; Surgery